PLoS Medicine (Apr 2010)

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis.

  • Beate Sander,
  • Jeffrey C Kwong,
  • Chris T Bauch,
  • Andreas Maetzel,
  • Allison McGeer,
  • Janet M Raboud,
  • Murray Krahn

DOI
https://doi.org/10.1371/journal.pmed.1000256
Journal volume & issue
Vol. 7, no. 4
p. e1000256

Abstract

Read online

BackgroundIn July 2000, the province of Ontario, Canada, initiated a universal influenza immunization program (UIIP) to provide free seasonal influenza vaccines for the entire population. This is the first large-scale program of its kind worldwide. The objective of this study was to conduct an economic appraisal of Ontario's UIIP compared to a targeted influenza immunization program (TIIP).Methods and findingsA cost-utility analysis using Ontario health administrative data was performed. The study was informed by a companion ecological study comparing physician visits, emergency department visits, hospitalizations, and deaths between 1997 and 2004 in Ontario and nine other Canadian provinces offering targeted immunization programs. The relative change estimates from pre-2000 to post-2000 as observed in other provinces were applied to pre-UIIP Ontario event rates to calculate the expected number of events had Ontario continued to offer targeted immunization. Main outcome measures were quality-adjusted life years (QALYs), costs in 2006 Canadian dollars, and incremental cost-utility ratios (incremental cost per QALY gained). Program and other costs were drawn from Ontario sources. Utility weights were obtained from the literature. The incremental cost of the program per QALY gained was calculated from the health care payer perspective. Ontario's UIIP costs approximately twice as much as a targeted program but reduces influenza cases by 61% and mortality by 28%, saving an estimated 1,134 QALYs per season overall. Reducing influenza cases decreases health care services cost by 52%. Most cost savings can be attributed to hospitalizations avoided. The incremental cost-effectiveness ratio is Can$10,797/QALY gained. Results are most sensitive to immunization cost and number of deaths averted.ConclusionsUniversal immunization against seasonal influenza was estimated to be an economically attractive intervention.